Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg
achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia …

Liposomes have become useful and well-known drug delivery vehicles because of their
ability to entrap drugs without chemically modifying them and to deliver them somewhat …

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for patients
suffering from chronic myeloid leukemia (CML). Testing for various mutations in the BCR …

Background. Breast cancer treatment trends are currently based on tailored therapies using
tumor and patient biomarkers. Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) …

Imatinib is a chemotherapeutic drug used for the treatment of chronic myeloid leukemia
(CML). Recent data showed imatinib‐induced cell death in various types of cancers …

In this work we propose to model chemotherapy taking into account the mutual interaction
between tumour growth and the development of tumour vasculature. By adopting a simple …

Background. Chronic myeloid leukemia (CML) is a progressive disease, consisting of three
phases, chronic, accelerated and blast phase. Treatment with imatinib has demonstrated …

STAT proteins are cytoplasmic transcription factors that are involved in the regulation of
numerous cellular activities such as cell growth, differentiation, and survival. In this study, we …

Due to the mutations of the Bcr/Abl oncogene that obstacle the binding of the protein with
imatinib, the resistance to imatinib has developed in a significant portion of chronic myeloid …

We investigated the effects of neferine (Nef) on STI571 sensitivity and the possible
mechanism in STI571-resistant K562/G01 cells. We observed cell proliferation by the …